Ying Kuen Cheung

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Simple sequential boundaries for treatment selection in multi-armed randomized clinical trials with a control
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, New York 10032, USA
    Biometrics 64:940-9. 2008
  2. ncbi request reprint Selecting promising ALS therapies in clinical trials
    Ying Kuen Cheung
    Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, USA
    Neurology 67:1748-51. 2006
  3. ncbi request reprint Continuous Bayesian adaptive randomization based on event times with covariates
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Stat Med 25:55-70. 2006
  4. pmc Selecting promising treatments in randomized Phase II cancer trials with an active control
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    J Biopharm Stat 19:494-508. 2009
  5. pmc Efficiency perspectives on adaptive designs in stroke clinical trials
    Ken Cheung
    Department of Biostatistics, Columbia University, 722 W 168th Street, New York, NY 10032, USA
    Stroke 42:2990-4. 2011
  6. pmc Calibration of prior variance in the Bayesian continual reassessment method
    Shing M Lee
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Stat Med 30:2081-9. 2011
  7. pmc Continual reassessment method with multiple toxicity constraints
    Shing M Lee
    Department of Biostatistics, Columbia University, New York, NY 10032, USA
    Biostatistics 12:386-98. 2011
  8. ncbi request reprint A simple technique to evaluate model sensitivity in the continual reassessment method
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 58:671-4. 2002
  9. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
  10. ncbi request reprint Exact two-sample inference with missing data
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 61:524-31. 2005

Research Grants

  1. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2006
  2. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2007
  3. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2009
  4. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2010

Detail Information

Publications16

  1. ncbi request reprint Simple sequential boundaries for treatment selection in multi-armed randomized clinical trials with a control
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, New York 10032, USA
    Biometrics 64:940-9. 2008
    ....
  2. ncbi request reprint Selecting promising ALS therapies in clinical trials
    Ying Kuen Cheung
    Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, USA
    Neurology 67:1748-51. 2006
    ....
  3. ncbi request reprint Continuous Bayesian adaptive randomization based on event times with covariates
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Stat Med 25:55-70. 2006
    ..We illustrate these methods by application to a phase II selection trial in acute leukaemia. A simulation study in the context of this trial is presented...
  4. pmc Selecting promising treatments in randomized Phase II cancer trials with an active control
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    J Biopharm Stat 19:494-508. 2009
    ..The operating characteristics of the proposed methods are compared to that of a single-stage design via simulations: The sample size requirement is reduced substantially and is feasible at an early stage of drug development...
  5. pmc Efficiency perspectives on adaptive designs in stroke clinical trials
    Ken Cheung
    Department of Biostatistics, Columbia University, 722 W 168th Street, New York, NY 10032, USA
    Stroke 42:2990-4. 2011
    ..This understanding is critical to appreciate the limitations, as well as the full promise, of adaptive designs, so that investigators can deploy an appropriate statistical design--be it adaptive or not--in a clinical study...
  6. pmc Calibration of prior variance in the Bayesian continual reassessment method
    Shing M Lee
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Stat Med 30:2081-9. 2011
    ..However, the new approaches yield a smaller interval of toxicity probabilities in which a neighboring dose may be selected...
  7. pmc Continual reassessment method with multiple toxicity constraints
    Shing M Lee
    Department of Biostatistics, Columbia University, New York, NY 10032, USA
    Biostatistics 12:386-98. 2011
    ..Based on simulations, our proposed methods achieve comparable accuracy in identifying the maximum tolerated dose but have better control of the erroneous allocation and recommendation of an overdose...
  8. ncbi request reprint A simple technique to evaluate model sensitivity in the continual reassessment method
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 58:671-4. 2002
    ..The technique presented is found to be a useful supplement to simulation when planning a phase I trial...
  9. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  10. ncbi request reprint Exact two-sample inference with missing data
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 61:524-31. 2005
    ..Monte Carlo approximation by the Gibbs sampler is proposed, and is shown to be fast and accurate via simulation. The method is illustrated in two small data sets for which asymptotic inferential procedures may not be appropriate...
  11. ncbi request reprint Monitoring the rates of composite events with censored data in phase II clinical trials
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 58:89-97. 2002
    ..Application to a leukemia trial with a composite event shows that the method can reduce trial duration substantially while maintaining the reliability of interim decisions...
  12. ncbi request reprint A Meta-Analysis of Differences in IQ Profiles Between Individuals with Asperger's Disorder and High-Functioning Autism
    Hsu Min Chiang
    Department of Health and Behavior Studies, Teachers College, Columbia University, New York, NY, USA
    J Autism Dev Disord 44:1577-96. 2014
    ..These findings seem to suggest that AspD and HFA are two different subtypes of Autism. The implications of the present findings to DSM-5 Autism Spectrum Disorder are discussed. ..
  13. ncbi request reprint A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation
    Manuela Orjuela
    Departments of Pediatrics, Columbia University, New York, New York 10032, USA
    Clin Cancer Res 9:3945S-52S. 2003
    ..The response rate to immunotherapy (rituximab) is only about 46% with a 54% relapse/progression rate. In this study, we investigated the use of a combination of Cy/Pred with rituximab as treatment for this disease...
  14. doi request reprint Factors associated with participation in employment for high school leavers with autism
    Hsu Min Chiang
    Intellectual Disability Autism Program, Department of Health and Behavior Studies, Teachers College, Columbia University, Box 223, 525 West 120th St, New York, NY 10027, USA
    J Autism Dev Disord 43:1832-42. 2013
    ..These findings may have implications for professionals who provide transition services and post-secondary programs for individuals with autism. ..
  15. ncbi request reprint A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients
    Ifeyinwa Osunkwo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, New York, USA
    Biol Blood Marrow Transplant 10:246-58. 2004
    ..Further pharmacokinetic and pharmacodynamic studies are ongoing in pediatric and adolescent AlloSCT recipients to define optimal MMF dosing...
  16. ncbi request reprint On the use of nonparametric curves in phase I trials with low toxicity tolerance
    Ying Kuen Cheung
    Division of Biostatistics, School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 58:237-40. 2002
    ..Interestingly, improvement can be achieved by prescribing slightly more informative priors. Some guidelines for prior elicitation are established using a connection between this curve-free method and the continual reassessment method...

Research Grants5

  1. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2006
    ....
  2. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2007
    ....
  3. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2009
    ....
  4. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2010
    ....